Antivirulence activity of azithromycin in Pseudomonas aeruginosa

被引：99

作者：

Imperi, Francesco ^{[1
,2
]}

Leoni, Livia ^{[3
]}

Visca, Paolo ^{[3
]}

机构：

[1] Sapienza Univ Rome, Cenci Bolognetti Fdn, Inst Pasteur, Rome, Italy

[2] Sapienza Univ Rome, Dept Biol & Biotechnol C Darwin, Rome, Italy

[3] Roma Tre Univ, Dept Sci, I-00146 Rome, Italy

来源：

FRONTIERS IN MICROBIOLOGY | 2014年 / 5卷

关键词：

antibiotic; cystic fibrosis; inflammation; macrolide; regulation; virulence; LONG-TERM AZITHROMYCIN; CYSTIC-FIBROSIS; SUBINHIBITORY CONCENTRATIONS; MACROLIDE ANTIBIOTICS; VIRULENCE FACTORS; BIOFILM FORMATION; LUNG-FUNCTION; IN-VITRO; SUB-MICS; INHIBITION;

D O I：

10.3389/fmicb.2014.00178

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Antibiotics represent our bulwark to combat bacterial infections, but the spread of antibiotic resistance compromises their clinical efficacy. Alternatives to conventional antibiotics are urgently needed in order to complement the existing antibacterial arsenal. The macrolide antibiotic azithromycin (AZM) provides a paradigmatic example of an "unconventional" antibacterial drug. Besides its growth-inhibiting activity, AZM displays potent anti-inflammatory properties, as well as antivirulence activity on some intrinsically resistant bacteria, such as Pseudomonas aeruginosa. In this bacterium, the antivirulence activity of AZM mainly relies on its ability to interact with the ribosome, resulting in direct and/or indirect repression of specific subsets of genes involved in virulence, quorum sensing, biofilm formation, and intrinsic antibiotic resistance. Both clinical experience and clinical trials have shown the efficacy of AZM in the treatment of chronic pulmonary infections caused by P. aeruginosa. The aim of this review is to combine results from laboratory studies with evidence from clinical trials in order to unify the information on the in vivo mode of action of AZM in P. aeruginosa infection.

引用

页数：7

共 73 条

[1] Biotic acts of antibiotics [J].

Aminov, Rustam I. .

FRONTIERS IN MICROBIOLOGY, 2013, 4

[2] Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? [J].

Amsden, GW .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (01) :10-21

[3] Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro [J].

Anderson, R. ;

Steel, H. C. ;

Cockeran, R. ;

Von Gottberg, A. ;

de Gouveia, L. ;

Klugman, K. P. ;

Mitchell, T. J. ;

Feldman, C. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (05) :1155-1158

[4]

Baumann Ulrich, 2004, Can Respir J, V11, P151

[5]

Blumer Jeffrey L, 2005, Int J Antimicrob Agents, V26 Suppl 3, pS143, DOI 10.1016/S0924-8579(05)80320-6

[6] Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability [J].

Buyck, Julien M. ;

Plesiat, Patrick ;

Traore, H. ;

Vanderbist, F. ;

Tulkens, Paul M. ;

Van Bambeke, Francoise .

CLINICAL INFECTIOUS DISEASES, 2012, 55 (04) :534-542

[7] The biology and future prospects of antivirulence therapies [J].

Cegelski, Lynette ;

Marshall, Garland R. ;

Eldridge, Gary R. ;

Hultgren, Scott J. .

NATURE REVIEWS MICROBIOLOGY, 2008, 6 (01) :17-27

[8] Targeting virulence: a new paradigm for antimicrobial therapy [J].

Clatworthy, Anne E. ;

Pierson, Emily ;

Hung, Deborah T. .

NATURE CHEMICAL BIOLOGY, 2007, 3 (09) :541-548

[9] Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial [J].

Clement, A. ;

Tamalet, A. ;

Leroux, E. ;

Ravilly, S. ;

Fauroux, B. ;

Jais, J-P .

THORAX, 2006, 61 (10) :895-902

[10]

Coggan KA, 2012, CURR ISSUES MOL BIOL, V14, P47

← 1 2 3 4 5 6 7 8 →